<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="http://www.adocia.com/" target=_blank>Adocia</A></STRONG>, a <A title="" href="https://www.aderly.com/biotechnologie-france-europe/life-science-biotechnology-cluster-france-europe,p,6,EN.jsp" target=_blank>biotech</A> company specialized in the formulation of therapeutic proteins for the treatment of diabetes and chronic wounds, announced that it had filed another three patent applications covering new formulations of monoclonal antibodies</STRONG>. More specifically, these patent applications relate to original formulations that facilitate the subcutaneous administration of antibodies, as well as <STRONG>innovative formulations that reduce antibody aggregation</STRONG>. <STRONG>Monoclonal antibodies are therapeutic proteins that are effective in treating numerous chronic diseases: <A title="" href="https://www.aderly.com/cancerologie/index,p,164,EN.jsp" target=_blank>cancer</A>, osteoporosis, multiple sclerosis and other inflammatory diseases</STRONG>. At present, these proteins are mostly administered intravenously. Subcutaneous administration is now the preferred method as it makes patients&#8217; lives easier and reduces the costs of treatment.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>Created seven years ago in the <A title="" href="https://www.aderly.com/sites-implantation/index,p,17,EN.jsp" target=_blank>Lyon area</A>, Adocia, which collaborates mainly with groups such as <A title="" href="http://www.novonordisk.fr/documents/home_page/document/index.asp" target=_blank>Novo Nordisk</A>, <A title="" href="https://www.lilly.fr/" target=_blank>Eli Lilly </A>and <A title="" href="http://www.sanofi.fr/l/fr/fr/index.jsp" target=_blank>Sanofi</A></STRONG> was recently floated on the stock market, on the NYSE Euronext market. It was the first flotation on the Paris stock market in 2012. <STRONG>Adocia is a member of <A title="" href="https://www.aderly.com/Infectiologie/index,p,157,EN.jsp" target=_blank>Lyonbiop&#244;le</A>, a center of excellence in vaccine and diagnostic labeled worldwide competitiveness cluster in 2005</STRONG>. Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public. &#8220;<EM><STRONG>Adocia is continuing to innovate in major <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>pharmaceutical</A> industry applications</STRONG></EM>&#8221;, said the company&#8217;s President &amp; CEO, G&#233;rard Soula. &#8220;<EM>The monoclonal antibody market represents a major opportunity for us, since it was worth $45 billion in 2011 and is expected to reach $58 billion in 2016</EM>.&#8221;<BR></P>